ALIVUS Share Price Performance
₹969.70
-68.50 (-6.60%)
Price ₹969.70
Share Price₹969.70
ALIVUS Community Narratives
There are no narratives available yet.
Recent ALIVUS News & Updates
Alivus Life Sciences Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 40.40
- Gross Margin
- 55.69%
- Net Profit Margin
- 20.65%
- Debt/Equity Ratio
- 2.0%
Alivus Life Sciences Limited Competitors
Snowflake Analysis
About ALIVUS
- Founded
- 2001
- Employees
- 2203
- CEO
- WebsiteView website
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. The company offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company exports its products. Alivus Life Sciences Limited was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Market Insight
Market sentiment on BTC treasury companies is moving, and with volatility rising, disagreements over their future prospects are as heated as ever.
Continue reading
Indian Market Performance
- 7 Days: 2.4%
- 3 Months: 1.8%
- 1 Year: -5.1%
- Year to Date: 0.3%
Over the last 7 days, the market has risen 2.4%, driven by gains in every sector, especially the Consumer Discretionary sector. Over the past year the market is down 5.1%. Looking forward, earnings are forecast to grow by 16% annually. Market details ›